

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

HEALTH TECHNOLOGY APPRAISAL PROGRAMME

Equality impact assessment – Guidance development

STA dabrafenib with trametinib for treating BRAF V600E mutation-positive glioma in children and young people

The impact on equality has been assessed during this appraisal according to the principles of the NICE equality scheme.

Final draft guidance

- | |
|--|
| 1. Have the potential equality issues identified during the scoping process been addressed by the committee, and, if so, how? |
| During scoping, consultees noted that the population in the marketing authorisation is restricted to 'paediatric patients aged 1 year and older' and that this contributes to inequality based on age. Because the committee is only able to make recommendations within the marketing authorisation, it concluded that this restriction did not represent an equality issue in its evaluation of clinical and cost effectiveness. |

- | |
|--|
| 2. Have any other potential equality issues been raised in the submissions, expert statements or academic report, and, if so, how has the committee addressed these? |
| No |

- | |
|--|
| 3. Have any other potential equality issues been identified by the committee, and, if so, how has the committee addressed these? |
| No |

4. Do the recommendations make it more difficult in practice for a specific group to access the technology compared with other groups? If so, what are the barriers to, or difficulties with, access for the specific group?

No

5. Is there potential for the recommendations to have an adverse impact on people with disabilities because of something that is a consequence of the disability?

No

6. Are there any recommendations or explanations that the committee could make to remove or alleviate barriers to, or difficulties with, access identified in questions 4 or 5, or otherwise fulfil NICE's obligations to promote equality?

No

7. Have the committee's considerations of equality issues been described in the final draft guidance, and, if so, where?

The committee's considerations of the equality issues are discussed in section 3.20 of the FDG.

Approved by Associate Director (name): ...Janet Robertson

Date: 10 April 2024